$MGTX News
Last published 2w ago
- 2w agoMGTXMeiraGTx Announces Four Posters at the European Society of Gene and Cell Therapy (ESGCT) 2026 Annual Congress and the Network of Excellence for ALS (NEALS) Annual MeetingGlobeNewswireLONDON and NEW YORK, Oct. 27, 2026 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical-stage genetic medicines company, today announced the Company will exhibit three posters at
- 2mo agoMGTXGraviton BioScience Corporation Announces Publication of Positive Ph1b Trial Results for GV101 (TDI01) in Chronic Graft versus Host Disease in Signal Transduction and Targeted Therapy, by Beijing Tide PharmaceuticalPR NewswireGraviton BioScience Corporation, a privately held, clinical-stage biotechnology company, announced the publication of peer-reviewed data from a...
- 3mo agoMGTXMeiraGTx Reports Second Quarter 2026 Financial and Operational ResultsGlobeNewswireReceived FDA Breakthrough Therapy Designation for AAV2-hAQP1 and reported positive three-year data from Phase 1 AQUAx clinical trial evaluating AAV2-hAQP1 for the treatment of moderate to severe grade 2/3
- 3mo agoMGTXGraviton BioScience Announces Clearance of Investigational New Drug (IND) for GV101 for the Treatment of Friedreich's AtaxiaPR NewswireGraviton received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA) for a novel capsule formulation of GV101 on August 7, 2026.FDA clearance marks a critical regulatory milestone
- 3mo agoMGTXMeiraGTx Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireLONDON and NEW YORK, Aug. 06, 2026 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical-stage genetic medicines company, today announced that the Compensation Committee of the
- 4mo agoMGTXMeiraGTx Announces $400 million Strategic Investment by Oberland Capital to Support Development and Commercialization of AAV2-hAQP1 and Botaretigene Sparoparvovec (bota-vec)GlobeNewswireMeiraGTx to receive up to $375 million in non-dilutive cash and up to $25 million in equity investmentFollowing regulatory approval, Oberland Capital to receive low single-digit capped royalties on the net sales of each
- 6mo agoMGTXMeiraGTx Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireLONDON and NEW YORK, May 14, 2026 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical-stage genetic medicines company, today announced that the Compensation Committee of the
- 6mo agoMGTXMeiraGTx Reports First Quarter 2026 Financial and Operational ResultsGlobeNewswireReceived FDA Breakthrough Therapy Designation for AAV2-hAQP1Reported positive three-year data from the Phase 1 AQUAx study of AAV2-hAQP1 for the treatment of grade 2/3 late radiation-induced xerostomiaEntered into an
- 6mo agoMGTXMeiraGTx Announces Pricing of $100 Million Offering of Ordinary SharesGlobeNewswireLONDON and NEW YORK, April 16, 2026 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical-stage genetic medicines company, today announced the pricing of an underwritten offering of
- 6mo agoMGTXMeiraGTx Announces the Acquisition of Botaretigene Sparoparvovec (bota-vec) for the Treatment of X-linked Retinitis Pigmentosa (XLRP)GlobeNewswireCompany entered into an asset purchase agreement with Johnson & Johnson (J&J) to acquire all interests in botaretigene sparoparvovec (bota-vec) for the treatment of X-linked retinitis pigmentosa (XLRP)MeiraGTx
- 6mo agoMGTXMeiraGTx Announces Positive Three-year Data from the Phase 1 AQUAx Clinical Study of AAV-hAQP1 for the Treatment of Grade 2/3 Late Radiation-Induced XerostomiaGlobeNewswireClinically meaningful improvements in xerostomia symptoms measured by PRO Xerostomia Questionnaire (XQ) maintained out to 3 years post treatment with AAV-hAQP1 for both bilateral and unilateral cohortsIncreases in
- 7mo agoMGTXMeiraGTx to Present 3-Year Data from the Phase 1 AQUAx Clinical Study of AAV-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia on Thursday, April 16, 2026GlobeNewswire- Presentation to include 3-year data from all cohorts of the Phase 1 AQUAx Clinical Study - Cohort-level data and individual patient data from bilateral and unilateral cohorts will be presented for both PRO and
- 7mo agoMGTXMeiraGTx Announces FDA Breakthrough Therapy Designation for AAV2-hAQP1 for the Treatment of Grade 2 and Grade 3 Radiation-Induced Xerostomia (RIX) and Reports Fourth Quarter and Full Year 2025 Financial and Operational ResultsGlobeNewswireFDA granted Breakthrough Therapy Designation for AAV2-hAQP1 for the treatment of Grade 2 and Grade 3 late xerostomia caused by radiotherapy for cancers of the upper aerodigestive tractMeiraGTx to hold a program update
- 8mo agoARWRJNJMGTXOTLC+1Why Late-Stage CNS, Oncology Assets Are Becoming the Hottest Targets in Biotech M&AGlobeNewswireAUSTIN, Texas, Feb. 17, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: Biotech dealmaking is increasingly defined by a clear strategic shift: Pharmaceutical companies are prioritizing de-risked, late-stage
- 9mo agoMGTXZipBio and MeiraGTx Enter into Exclusive License Agreement to Advance First-in-Class AAV Gene Therapy for Geographic AtrophyPR NewswireZipBio, a biotechnology company pioneering AI-driven protein therapeutics, announced an exclusive license agreement with MeiraGTx Holdings plc...
- 11mo agoMGTXGraviton Bioscience to Present Selective ROCK2 Obesity Data at 8th Annual Evercore HealthCONx ConferencePR NewswireGraviton Bioscience Corporation, a clinical-stage biotechnology company developing selective ROCK2 inhibitors for metabolic, inflammatory, fibrotic,...
- 12mo agoMGTXMeiraGTx Reports Third Quarter 2025 Financial and Operational ResultsGlobeNewswireEntered into broad strategic collaboration with Eli Lilly and Company ("Lilly") in the area of ophthalmology, granting Lilly worldwide exclusive rights to the Company's AAV-AIPL1 program for treatment of one of the
- 1y agoMGTXMeiraGTx Enters into Strategic Collaboration with Eli Lilly and Company to Develop and Commercialize Genetic Medicines in OphthalmologyGlobeNewswireLONDON and NEW YORK, Nov. 10, 2025 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage genetic medicines company, today announced a broad strategic collaboration in the area
- 1y agoMGTXMeiraGTx Announces Two Posters at the European Society of Gene and Cell Therapy (ESGCT) 2025 Annual CongressGlobeNewswireLONDON and NEW YORK, Oct. 07, 2025 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical-stage genetic medicines company, today announced the Company will exhibit two posters at the
- 1y agoMGTXMeiraGTx Reports Second Quarter 2025 Financial and Operational ResultsGlobeNewswire- Gained alignment with U.S. Food and Drug Administration (FDA) on the ongoing Phase 2 AQUAx2 randomized double-blind, placebo-controlled pivotal study in Grade 2/3 radiation-induced xerostomia (RIX) to support a
- 1y agoMGTXMeiraGTx Announces the Presentation of Four Posters at the American Society of Gene and Cell Therapy (ASGCT) 2025 Annual MeetingGlobeNewswireLONDON and NEW YORK, May 13, 2025 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage genetic medicines company, today announced the Company will exhibit four poster
- 1y agoMGTXMeiraGTx Reports First Quarter 2025 Financial and Operational ResultsGlobeNewswire- Announced strategic collaboration with Hologen AI, including a $200 million cash upfront payment to MeiraGTx and the formation of a joint venture, Hologen Neuro AI Ltd, with a further $230 million in capital committed
- 1y agoMGTXMeiraGTx Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for AAV-GAD for the Treatment of Parkinson's DiseaseGlobeNewswire- This RMAT designation is based on data from 3 clinical studies demonstrating the potential benefit of AAV-GAD as a one-time treatment for Parkinson's disease - RMAT designation includes the benefits of the Fast
- 1y agoMGTXMeiraGTx Reports Fourth Quarter and Full Year 2024 Financial and Operational Results and Recent Business UpdatesGlobeNewswire- Today announced strategic collaboration with Hologen AI, including a $200 million upfront payment to MeiraGTx and the formation of a joint venture, Hologen Neuro AI Ltd, with a further $230 million in capital
- 1y agoMGTXMeiraGTx Enters into a Strategic Collaboration with Hologen AI to Expedite Phase 3 Development of AAV-GAD for Parkinson's Disease and Industrialize MeiraGTx's Proprietary Manufacturing ProcessGlobeNewswire- MeiraGTx to receive $200 million in upfront cash consideration - MeiraGTx and Hologen will form a joint venture, Hologen Neuro AI Ltd, with an additional $230 million committed capital from Hologen to fund 100% of
- 1y agoMGTXMeiraGTx Announces The Lancet Publication of Data Demonstrating the Efficacy of rAAV8.hRKp.AIPL1 for the Treatment of Leber Congenital Amaurosis 4 (LCA4) Retinal DystrophyGlobeNewswireAs disclosed in the paper, 4 out of 4 young children with the AIPL1-related retinal dystrophy, LCA4, benefited substantially from unilateral subretinal administration of rAAV8.hRKp.AIPL1 with improved visual acuity,
- 1y agoMGTXMeiraGTx Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for AAV2-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced XerostomiaGlobeNewswire- RMAT designation recognizes the preliminary clinical evidence of the potential benefit of AAV2-hAQP1 as a one-time treatment for this debilitating condition - RMAT designation includes the benefits of the Fast Track
- 1y agoTLPHOLMASYNACTMGTX+1Ascentage Pharma Appoints Ms. Marina S. Bozilenko and Dr. Debra Yu as Independent Non-Executive DirectorsPR NewswireAscentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing and commercializing therapies to address global...
- 1y agoMGTXMeiraGTx Announces Third Quarter 2024 Financial and Operational Results and Recent Business UpdatesGlobeNewswireReceived 3 Rare Pediatric Disease Designations (RPDD) from FDA for each of 3 potential therapies for 3 different rare inherited retinopathies including AAV-AIPL1 Agreed on pathway with MHRA for Marketing Authorization
- 2y agoMGTXMeiraGTx Announces Five Posters at the European Society of Gene and Cell Therapy (ESGCT) 2024 Annual CongressGlobeNewswireLONDON and NEW YORK, Oct. 22, 2024 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical-stage genetic medicines company, today announced the Company will exhibit five posters at
- 2y agoMGTXMeiraGTx Announces Positive Data from Randomized, Sham-controlled Clinical Bridging Study of AAV-GAD for the Treatment of Parkinson's DiseaseGlobeNewswireThe primary study objective of safety and tolerability was met Significant and clinically meaningful improvements from baseline demonstrated for key efficacy endpoints at 26 weeks Significant improvement of 18 points
- 2y agoMGTXMeiraGTx Announces Poster Presentation on a Potential Treatment for MC4R Genetic Deficiency at the 2024 Society for Neuroscience ConferenceGlobeNewswireLONDON and NEW YORK, Oct. 09, 2024 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage genetic medicine company, today announced a poster presentation at the 2024 Society
- 2y agoMGTXMeiraGTx Announces $50 Million Offering of Ordinary Shares led by Sanofi and Reports Second Quarter 2024 Financial and Operational ResultsGlobeNewswire- Positive data from the Phase 1 AQUAx study in radiation-induced xerostomia (RIX) presented at the American Academy of Oral Medicine 2024 annual meeting (AAOM) showed meaningful improvements in patient-reported outcomes
- 2y agoMGTXMeiraGTx Announces Pricing of Offering of Ordinary Shares Led by SanofiGlobeNewswireLONDON and NEW YORK, Aug. 12, 2024 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage genetic medicine company, today announced the pricing of an underwritten offering of
- 2y agoMGTXMeiraGTx Reports First Quarter 2024 Financial and Operational ResultsGlobeNewswire- Positive data from the Phase 1 AQUAx study in radiation-induced xerostomia (RIX) presented in an oral session at the American Academy of Oral Medicine 2024 annual meeting (AAOM) April 17-20, 2024 - Received $50
- 2y agoMGTXMeiraGTx to Participate in Upcoming Investor ConferencesGlobeNewswireLONDON and NEW YORK, April 24, 2024 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced that Alexandria Forbes, Ph.D., President and
- 2y agoMGTXMeiraGTx Announces Oral Presentation at the 2024 American Academy of Oral Medicine (AAOM) Annual ConferenceGlobeNewswireLONDON and NEW YORK, April 18, 2024 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced the Company gave an oral presentation at the
- 2y agoMGTXMeiraGTx Reports Fourth Quarter and Full Year 2023 Financial and Operational Results and Recent Business UpdatesGlobeNewswire- Company aligned with FDA on requirements for ongoing Phase 2 AQUAx2 clinical trial for Grade 2/3 radiation-induced xerostomia to be considered pivotal supporting potential BLA filing - Company to present
- 2y agoMGTXMeiraGTx Announces $50 Million Milestone from Janssen PharmaceuticalsGlobeNewswireLONDON and NEW YORK, Feb. 13, 2024 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced the achievement of the first milestone under the
- 2y agoMGTXGraviton Bioscience Announces Strategic Investment from Sanofi to Advance Development of the Next Generation of Selective ROCK2 InhibitorsPR NewswireGraviton Bioscience, a privately held clinical-stage biotechnology company focused on therapies that inhibit Rho/Rho-associated coiled-coil...
- 2y agoMGTXMeiraGTx Announces Asset Purchase Agreement Involving its AAV-RPGR Collaboration for up to $415 millionGlobeNewswire- MeiraGTx enters into an Asset Purchase Agreement related to botaretigene sparoparvovec (bota-vec, formerly AAV-RPGR) for the treatment of X-linked retinitis pigmentosa (XLRP) for a total of up to $415 million -
- 2y agoMGTXMeiraGTx to Participate in Upcoming Investor ConferencesGlobeNewswireLONDON and NEW YORK, Nov. 21, 2023 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced that Alexandria Forbes, Ph.D., President and
- 2y agoMGTXMeiraGTx Announces Third Quarter 2023 Financial and Operational ResultsGlobeNewswire- Received strategic investment from Sanofi purchasing $30 million of ordinary shares of the Company at a price of $7.50 per share in October 2023 - Announced a right of first negotiation (ROFN) with Sanofi for
- 3y agoMGTXMeiraGTx Announces $30 Million Strategic Investment from Sanofi; Company Pursuing Multiple Additional Strategic OpportunitiesGlobeNewswireSanofi to purchase $30 million of ordinary shares of the Company at a price of $7.50 per share Sanofi to receive a right of first negotiation (ROFN) for the use of MeiraGTx's Riboswitch gene regulation technology for
- 3y agoMGTXMeiraGTx Announces an Oral Presentation and Eight Posters at the European Society of Gene and Cell Therapy (ESGCT) 2023 Annual CongressGlobeNewswireLONDON and NEW YORK, Oct. 24, 2023 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced the Company will exhibit eight posters and
- 3y agoMGTXMeiraGTx Reports Second Quarter 2023 Financial and Operational ResultsGlobeNewswirePhase 3 LUMEOS clinical trial of botaretigene sparoparvovec (bota-vec, formerly AAV-RPGR) for the treatment of X-linked retinitis pigmentosa (XLRP) enrollment target has now been surpassedAnnounced positive clinical data
- 3y agoMGTXMeiraGTx Announces Poster Presentation at the 2023 American Society of Gene and Cell Therapy (ASGCT) Spotlight on Immuno-OncologyGlobeNewswireLONDON and NEW YORK, Aug. 01, 2023 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced a poster presentation at the 2023 American
- 3y agoMGTXMeiraGTx Announces its Wholly-Owned Gene Therapy Manufacturing Facility in Shannon, Ireland has Received Commercial MIA Authorization for QC TestingGlobeNewswireLONDON and NEW YORK, July 19, 2023 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced that after a successful inspection by the Irish
- 3y agoMGTXMeiraGTx Announces Positive Clinical Data from the AQUAx Phase 1 Clinical Study of AAV2-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced XerostomiaGlobeNewswireClinically meaningful improvements in xerostomia symptoms measured by two different xerostomia PROs demonstrated across both unilaterally and bilaterally treated cohorts at 12 monthsIncreases in whole saliva flow rates
- 3y agoMGTXMeiraGTx to Present 12-month Data from All Cohorts of the Completed Phase 1 AQUAx Clinical Study and an Update on the Company's Recently Initiated Phase 2 Study of AAV-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia on Tuesday, June 27, 2023GlobeNewswireLONDON and NEW YORK, June 22, 2023 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced it will host a conference call and webcast to